| Literature DB >> 32599421 |
Robert Brünjes1, Thilo Hofmann2.
Abstract
The increasing use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging is leading to widespread contamination of freshwater and drinking water systems. Contrary to previous assumptions that GBCAs are stable throughout the water cycle, they can degrade. The stability of GBCAs depends largely on their organic ligands, but also on the physicochemical conditions. There is specific concern regarding UV end-of-pipe water treatments, which may degrade GBCAs. Degradation products in drinking water supplies can increase the risk of adverse health effects. This is of particular relevance where the raw water for drinking water production has a higher proportion of recycled wastewater. GBCAs concentrations in aquatic systems, often referred to as anthropogenic gadolinium, are determined using a variety of calculation methods. Where anthropogenic gadolinium concentrations are low, the inconsistent use of these methods results in high discrepancies and high levels of uncertainty. The current COVID-19 crisis will, in the short-term, drastically decrease the input of GBCAs to freshwater systems. Temporal variations in anthropogenic gadolinium concentrations in river water can be used to better understand river-aquifer interactions and groundwater flow velocities. Collecting urine from all patients following MRI examinations could be a way forward to halt the generally increasing concentrations of Gd in drinking water systems and recover this technologically critical element.Entities:
Keywords: Anthropogenic gadolinium; COVID-19; Drinking water; Gadolinium anomaly; Gadolinium-based contrast agents; Micropollutants
Mesh:
Substances:
Year: 2020 PMID: 32599421 PMCID: PMC7256513 DOI: 10.1016/j.watres.2020.115966
Source DB: PubMed Journal: Water Res ISSN: 0043-1354 Impact factor: 11.236
Characteristics and stability properties of approved gadolinium-based contrast agents (worldwide).
| Name | Acronym | Gd-DTPA | Gd-DTPA-BMA | Gd-DTPA-BMEA | Gd-BOPTA | Gd-EOB-DTPA | Gd-DOTA | Gd-HP-DO3A | Gd-BT-DO3A |
|---|---|---|---|---|---|---|---|---|---|
| Generic name | Gadopentetate dimeglumine | Gadodiamide | Gadoversetamide | Gadobenate dimeglumine | Gadoxetate disodium | Gadoterate meglumine | Gadoteridol | Gadobutrol | |
| Trade name | Magnevist® | Omniscan® | OptiMARK® | MultiHance® | Primovist®/Eovist® | Dotarem®/Artirem® | ProHance® | Gadovist®/Gadavist® | |
| Manufacturer | Bayer HealthCare | GE Healthcare | Guerbet | Bracco | Bayer HealthCare | Guerbet | Bracco | Bayer HealthCare | |
| Year of FDA approval | 1988 | 1993 | 1999 | 2004 | 2008 | 2013 | 1992 | 2011 | |
| Current legal status (Europe) | restricted to intra-articular | suspended | suspended | restricted to liver scans | maintained | maintained | maintained | maintained | |
| Type | linear | linear | linear | linear | linear | macrocyclic | macrocyclic | macrocyclic | |
| Charge | di-ionic | non-ionic | non-ionic | di-ionic | di-ionic | ionic | non-ionic | non-ionic | |
| Concentration | [M] | 0.5 | 0.5 | 0.5 | 0.5 | 0.25 | 0.5 | 0.5 | 1 |
| Standard dose | [mmol/kg] | 0.1 | 0.1 | 0.1 | 0.1 | 0.025 | 0.1 | 0.1 | 0.1 |
| Excess Ligand | 0.10% | 5% | 10% | none | 0.50% | none | 0.10% | 0.10% | |
| log Ktherm | [1] | 22.1 | 16.9 | 16.6 | 22.6 | 23.46 | 25.6 | 23.8 | 21.8 |
| log Kcond | [1] | 17.7 | 14.9 | 15 | 18.4 | 18.7 | 19.3 | 17.1 | 14.7 |
| log Kcond | [2] | 18.4 | 14.9 | 15 | 18.4 | 18.7 | 17.2 | 17.1 | 16.1 |
| log Kcond calculated for pH 4.0 | [2] | 11.2 | 10.8 | 10.8 | 11.1 | 11.5 | 9.5 | 9.9 | 9 |
| log Kcond (modelled) | [3] | 6.30 | 4.17 | not available | not available | not available | 7.24 | not available | not available |
| Kinetic stability (dissociation half-life at pH 1.0) | [1] | 10 min | 35 s | not available | not available | not available | >1 month | 3 h | 24 h |
Log Ktherm and log Kcond are the thermodynamic and conditional stability constants, respectively; [1] Morcos (2008) and references therein, [2] Le Fur and Caravan (2019), [3] Prybylski et al. (2017).
Fig. 1Total annual MRI examinations: global distribution based on the latest data available (Organisation for Economic Cooperation and Development (OECD), 2017). Data from Austria, Great Britain, New Zealand, Switzerland, and Portugal are restricted to in-hospital data.
Fig. 2Due to COVID-19 and its implications, changing anthropogenic gadolinium concentrations in surface water and groundwater could be used to improve the understanding of complex environmental systems.
Selected methods for calculating Gdanth; elements and approaches used.
| Reference | Elements used | Interpolation/extrapolation | Specifics |
|---|---|---|---|
| Sm, Tb | linear | Gd behaves as a LREE | |
| Nd, Dy | linear | Gd behaves as a MREE | |
| Sm, Dy | logarithmic | Gd behaves as a HREE | |
| Eu, Nd | logarithmic | Not usable if MREE are enriched or water is slightly acidic, rich in organic colloids | |
| Pr, Nd, Sm | geometric | Gd behaves as a LREE | |
| all Ln except Ce, Eu | third grade polynomial fit | no implicit assumption about the behavior of Gd |
No specifics stated in the original manuscript but implied in (Bau et al., 2006); LREE - light rare earth element, MREE - middle rare earth element, HREE - heavy rare earth element (terminology is referring to the original literature).
Fig. 3a Calculated gadolinium anomalies in water samples using different interpolation or extrapolation methods. Grey shading: area of reported Gd anomalies (max. 1.5) that have been assumed to be natural; b published data from water samples with Gd anomalies of less than 1.5 (averaged over selected methods); c published data from water samples with Gd anomalies greater than 1.5 (averaged over selected methods).